LEGN Legend Biotech
- 45.530
- +0.270+0.60%
Legend Biotech News
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)
HC Wainwright & Co. : Legendary Creatures (LEGN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $87.00.
Legend Biotech Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $87 Price Target
Hold Rating on Legend Biotech Amidst Approval of Carvykti and Commercial Manufacturing Challenges
Scotiabank Upgrades Legend Biotech to Sector Outperform
Analyst Ratings For Legend Biotech
Scotiabank Upgrades Legend Biotech to Sector Outperform, Maintains Price Target to $65
Scotiabank: Legendary Creatures (LEGN.US) rating was raised from being on par with the market to outperforming the market rating, and the target price was adjusted from $65.00 to $65.00.
Buy Rating Affirmed for Legend Biotech Amidst Anticipated Growth and Expanded Carvykti Use
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)
HC Wainwright & Co. : Legendary Creatures (LEGN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $87.00.
Legend Biotech Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $87 Price Target
Buy Rating Affirmed for Legend Biotech Amidst Growth Prospects and CARVYKTI's Market Expansion
Analysts Offer Insights on Healthcare Companies: Animalcare (GB:ANCR), Ansell (OtherANSLF) and Legend Biotech (LEGN)
Analysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)
Buy Rating Affirmed for Legend Biotech Following FDA Approval and Positive Growth Outlook
Analysts Conflicted on These Healthcare Names: Legend Biotech (LEGN), Intuitive Surgical (ISRG) and Disc Medicine (IRON)
Legend Biotech (LEGN) Gets a Buy From Piper Sandler
Analysis
Price Target
No Data
